JMP Securities has initiated coverage on Vigil Neuroscience Inc (NASDAQ: VIGL), noting the company's focus on neurodegenerative diseases.
Vigil's lead development candidate, VGL101, is a fully human monoclonal antibody agonist of TREM2 for axonal spheroids and pigmented glia (ALSP), a rare, genetically defined, and fatal neurodegenerative disease caused by microglial dysfunction.
The analysts Jason Butler and Roy Buchanan initiate with a Market Outperform rating and a price target of 23.
The analysts note that the strategy and the expertise assembled by the company can reduce translational development risk ...